ClinicalTrials.gg

Program

Trazodone

Also written as “Trazodone HCl”, “Trazodone 20 mg” and “150 mg trazodone hydrochloride”.

Its studies are mostly in Depression · Diabetic Neuropathies · Depressive Disorder, Major · Sleep Wake Disorders, led by 4 companies.

Furthest: phase 3, since Mar 12, 201414 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Angelini Pharma50 open or runningphase 3since Mar 12, 2014Mar 12, 2014none ahead
Labopharm50 open or runningphase 3since Oct 17, 2008Oct 17, 2008none ahead
Lee's Pharmaceutical30 open or runningphase 3since Jan 13, 2012Jan 13, 2012none ahead
Targeted Medical Pharma10 open or runningphase 3since Nov 5, 2011Nov 5, 2011none ahead

Also a collaborator on its studies: chiltern-international-inc, cross-research-s-a, eresearch-technology-inc and algorithme-pharma-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 17, 2008First study: phase 3 study in Depressive Disorder, MajorNew to LabopharmLabopharm · NCT00775203 · 412 enrolled · United States, Canada
  2. Feb 6, 2009Phase 1 study in HealthyLabopharm · NCT00839072 · 24 enrolled · Canada
  3. May 10, 20103 phase 1 studiesLabopharm · NCT01121926, NCT01121913, NCT01121900
  4. Nov 5, 2011Targeted Medical Pharma's first study: phase 3 study in Sleep Wake DisordersNew to Targeted Medical PharmaTargeted Medical Pharma · NCT01468038 · 111 enrolled · United States
  5. Jan 13, 2012Lee's Pharmaceutical's first study: phase 3 study in DepressionNew to Lee's PharmaceuticalLee's Pharmaceutical · NCT01524497 · 382 enrolled · China
  6. Mar 12, 2014Angelini Pharma's first study: phase 3 study in Depressive Disorder, MajorNew to Angelini PharmaAngelini Pharma · NCT02086929 · 364 enrolled · Austria, Czech Republic, Italy and more
  7. May 24, 20162 phase 1 studies in DepressionLee's Pharmaceutical · NCT02785614, NCT02785601
  8. Jun 23, 2017Phase 2 study in Diabetic NeuropathiesAngelini Pharma · NCT03202979 · 142 enrolled · Czechia, Hungary, Poland
  9. Apr 24, 2018Phase 1 study in HealthyAngelini Pharma · NCT03516630 · 20 enrolled · Switzerland
  10. Nov 20, 2018Phase 2 study in Diabetic NeuropathiesAngelini Pharma · NCT03749642 · 240 enrolled · Czechia, France, Poland and more
  11. Dec 20, 2024Phase 1 study in Bioavailability Heathy VolunteersAngelini Pharma · NCT06773767 · 64 enrolled · Germany

TargetBeta

“Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist”ChEMBL 37, by rule

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06773767Bioavailability Heathy Volunteers · Germany1CompletedAngelini PharmaAug 7, 202464
NCT03749642Diabetic Neuropathies · Czechia, France, Poland and more2CompletedAngelini PharmaJun 6, 2020240
NCT03516630Healthy · Switzerland1CompletedAngelini PharmaMay 1, 201720
NCT03202979Diabetic Neuropathies · Czechia, Hungary, Poland2CompletedAngelini PharmaAug 9, 2018142
NCT02785614Depression · Hong Kong1CompletedLee's PharmaceuticalNov 30, 201712
NCT02785601Depression · Hong Kong1CompletedLee's PharmaceuticalNov 30, 201715
NCT02086929Depressive Disorder, Major · Austria, Czech Republic, Italy and more3CompletedAngelini PharmaApr 2014364
NCT01524497Depression · China3CompletedLee's PharmaceuticalAug 2013382
NCT01468038Sleep Wake Disorders · United States3CompletedTargeted Medical PharmaOct 2008111
NCT01121926Healthy Subjects1CompletedLabopharmMar 200830
NCT01121913Healthy1CompletedLabopharmApr 200524
NCT01121900Healthy1CompletedLabopharmJul 200826
NCT00839072Healthy · Canada1CompletedLabopharmFeb 200924
NCT00775203Depressive Disorder, Major · United States, Canada3CompletedLabopharmNov 2007412

How it is read

Names in the registry

  • “Trazodone HCl”, 10 entries
  • “Trazodone”, 3 entries
  • “Trazodone 20 mg”, 2 entries
  • “150 mg trazodone hydrochloride”, 1 entry
  • “300 mg trazodone hydrochloride”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.